Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia Meeting Abstract


Authors: Lamanna, N.; Kalaycio, M.; Maslak, P.; Heaney, M. L.; Brentjens, R.; Jurcic, J.; Biederman, E.; Gencarelli, A. N.; Panageas, K. S.; Scheinberg, D. A.; Weiss, M. A.
Abstract Title: Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia
Meeting Title: 47th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 106
Issue: 11 Pt. 1
Meeting Dates: 2005 Dec 10-13
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2005-11-01
Start Page: 601A
End Page: 602A
Language: English
ACCESSION: WOS:000233426003489
PROVIDER: wos
PUBMED: 16342400
Notes: --- - Meeting Abstract: 2127 - 47th Annual Meeting of the American-Society-of-Hematology - DEC 10-13, 2005 - Atlanta, GA - Part 1 - "Source: Wos"